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ABSTRACT 
The population of people who use drugs (PWUD) has the highest prevalence of 
hepatitis C virus (HCV) infections in Europe. PWUD are multimorbid patients that are 
difficult to integrate into existing healthcare systems. In our study, we evaluated 
feasibility of providing HCV treatment within opioid maintenance treatment (OMT) 
programs offering integrated primary care based health services under one roof.  
We evaluated 66 charts of patients in four outpatient clinics (OMT) with HCV treatment 
(between 2002 and 2010). 14 of the patients were treated with heroin and 9 patients 
had a HIV co-infection. Data on socio-economic characteristics and quality of life were 
assessed. We counted the number of consultations in the clinic to assess how much 
supportive care the patients needed. 
62% of all patients (41 of 66) achieved sustained virological response (SVR). 84% of 
patients with genotype 3 achieved SVR. 64% of patient treated with heroin achieved 
SVR. The majority of patients (71%) used illicit drugs during HCV treatment and over 
80% were diagnosed with psychiatric co-morbidities. Comparisons of patient 
characteristics according to SVR or non-SVR showed a longer duration of OMT, more 
consultations per week during HCV treatment and poor self-reported physical condition 
were associated with non-SVR.  
 
We conclude that offering HCV treatment in an integrated primary care based setting 
with OMT and individualised use of different supporting strategies allows for treatment 
success rates in the population of PWUD which is comparable to the ones in the 
population of patients without drug use. Heroin maintenance treatment programs offer 
a feasible and safe setting for providing HCV treatment. 
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INTRODUCTION  
Hepatitis C infections are widely spread in the population of former and current 
injecting drug users causing significant morbidity and mortality among them (1, 2). 
There are an estimated 170 million people around the world carrying the hepatitis C 
virus (HCV) (1, 3) and in the population of people who use drugs (PWUD) the 
estimated prevalence of HCV antibodies varies between 60-80% (4). In Switzerland 
PWUD show the highest prevalence of HCV infection (5).  
PWUDs are patients with high rates of psychiatric and somatic co-morbidities and 
multiple substance abuse is common. PWUD are a group of multimorbid patients that 
is known to be hard to reach and particularly difficult to integrate into existing health 
care systems. Even though treatment for HCV infection exists with rates of sustained 
virological response (SVR) in more than 50% of patients, the population of PWUD is 
rarely treated (6). Studies have showed the feasibility of HCV treatment in this 
population (7-10), but eligibility remains low because patients with on-going illicit drug 
use, alcohol consumption, psychiatric co-morbidities or HIV infection are often 
excluded from treatment. 
Because of their complex needs, opioid-dependent patients are often treated in 
specialised, multidisciplinary opioid maintenance treatment (OMT) programs. OMT 
programs usually focus on addiction and psychiatric conditions, while physical 
conditions are neglected. In OMT programs, patients might have on-site access to 
basic primary health care. For more specialised treatments, as HCV requires, they 
have to be referred to secondary or tertiary care specialists. In these off-site clinics, the 
complex medical and psychosocial conditions of PWUD and the anticipation of 
potential psychiatric side effects can act as a barrier to starting HCV treatment. 
At the individual level, the main indication for hepatitis C treatment is to prevent end-
stage liver disease and liver cancer. At public health level, scaling up treatment uptake 
in this heavily affected population could contribute to reducing the epidemic (11). One 
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way to achieve this could be to develop and provide appropriate integrated settings for 
this marginalised group of patients in order to enhance their eligibility for treatment 
uptake.  
 
Arud runs four outpatient clinics for addiction medicine in Zurich, Switzerland, offering 
integrated primary care based interdisciplinary health services all under one roof. In 
this setting, patients are being treated for their addiction as well as their psychiatric co-
morbidities. Opioid-dependent patients can be treated with methadone, buprenorphine, 
long-acting morphine and prescribed heroin, depending on their individual situation and 
needs. In each clinic, on-site primary medical care is available including infectious 
diseases specialist care for HCV and HIV assessment and treatment.  
 
The objective of this study is to analyse the outcome of HCV treatments in the 
integrated primary care based outpatient clinics providing HCV care for a population 
that is difficult to treat, including patients with on-going use of illicit drugs and alcohol 
and with psychiatric co-morbidities. In addition, we aimed to investigate patient 
characteristics associated with HCV treatment outcome.  
 
METHODS 
Study design and patient population 
We conducted a retrospective chart review of all patients in the primary care based 
outpatient clinics for addiction medicine with HCV treatment for the period from 2002 to 
2010.  
Psychiatrists and psychologists were responsible for the substance abuse counselling 
including opioid substitution with methadone, buprenorphine and long-acting morphine. 
We also included patients who were treated with heroin in the heroin maintenance 
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treatment (HMT) program during the same period. Primary care specialists and 
internists provided comprehensive medical services throughout the study. The fulltime 
staff in our outpatient clinics included nurses and social workers. According to stability 
and physical and mental wellbeing, the patients were seen by our clinic staff at different 
intervals from daily to at least once a week. With the exception of prescribed heroin, 
which has to be consumed daily at the clinic, patients were allowed to get up to 6 take-
home doses of the substitution medication per week. If required, our patients had 
access to a walk-in clinic at all times with medical and psychiatric staff at their disposal. 
Internists and primary care specialists were responsible for HCV treatment. If 
necessary, they consulted with off-site hepatologists to discuss patient care issues. 
Specially trained nurses were involved in every consultation providing medical and 
psychosocial support, side effect management and information about the disease and 
treatment. 
All patients signed an informed consent form about using their anonymised data for this 
study. 
 
Treatment protocol  
All patients in OMT programs with chronic hepatitis C (twice positive for HCV 
antibodies and HCV RNA) were informed about the possibility of HCV treatment at our 
clinics. HCV treatment was offered to all interested patients who did not show any 
contraindications such as uncontrolled substance abuse, uncontrolled depression, 
psychosis or a severe concurrent medical disease. Importantly, reported illicit drug use 
(heroin, cocaine, cannabinoids or non-prescribed benzodiazepine) and/or intake of 
alcohol, injecting drug use or psychiatric co-morbidities were no contraindication per se 
for the start of HCV treatment in our study. Patients who consumed substances were 
offered treatment as long as their consumption happened in a controlled manner. Our 
definition of controlled substance use means consuming according to rules for safer 
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use and in modest amounts so as not to impair adherence to treatment. We also 
included patients with HIV co-infections as well as patients on prescribed heroin. 
Before starting HCV treatment, the patients underwent the following examinations: 
clinical examination by a psychiatrist, standard medical examination by an internist or 
primary care specialist, an assessment of liver disease and a baseline blood test. HCV 
genotype and HCV RNA (IU ml -1) were quantified at baseline and an abdominal 
ultrasound was performed. A liver biopsy was not a prerequisite for treatment.  
The HCV treatment and monitoring was carried out according to EASL guidelines with 
once weekly pegylated interferon α-2a (180ug/week) or α-2b (1.5ug/kg/week) plus 
weight-based ribavarin orally twice daily. The patients could inject the interferon at 
home or receive the injections at the clinic (either self-administered or given by a 
nurse). Ribavarin was dispensed in daily doses and take-homes were given up to a 
month’s supply, depending on the individual situation of each patient.  
In the first four weeks of HCV treatment, all patients attended the clinic at least once a 
week to be assessed for haematological and liver parameters and clinical side effects. 
After the initial four weeks, they were offered to attend the clinic once weekly or more if 
needed. They could make an appointment or just drop in to see the internist, the nurse 
or the psychiatrist. In week 12, 24 and 48, and again 24 weeks after the end of 
treatment, consultations were mandatory to evaluate the treatment. 
 
Outcome measures and assessments  
The primary outcome of our study was sustained virological response (SVR) defined as 
undetectable HCV RNA (<30 IU ml-1) in serum six month after the end of treatment. A 
secondary outcome was to determine patient characteristics associated with treatment 
success. 
The psychiatric co-morbidities including the substance dependences were diagnosed 
by the psychiatrists and referred to the ‘International Statistical Classification of 
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Diseases and Related Health Problems’ (ICD 10). Data on socio-economic 
characteristics and quality of life was collected by means of a questionnaire. The data 
collection on socio-economic characteristics included questions about the patient’s 
current housing situation, i.e. whether they were living by themselves or with a partner, 
whether they were having permanent accommodation or not and where they got their 
income from (employment, disability benefits or social welfare). The quality of life was 
assessed by a self-administrated questionnaire asking about the current mental, 
physical and socio-economic condition (good, moderate, poor). The patients were also 
asked to declare their use of illicit drugs and intake of alcohol. If they used illicit 
substances at least once during the HCV treatment, they were counted as positive for 
illicit drug use. In the same way they counted as patients who use injecting drugs 
(PWUJD) during the HCV treatment if they injected substances at least once. The 
intake of alcohol was also asked by self-report (intake on regular basis = more than 
50g/week). The use of illicit substances and alcohol was asked before starting and 
during HCV treatment. We counted the number of consultations in the clinic to assess 
how much supportive care they needed. 
 
Statistical analyses 
Descriptive statistics were calculated for all variables and presented as median 
(interquartile range) or frequency as appropriate. Patients were categorized into two 
groups according to their HCV treatment success (i.e. SVR and non-SVR). Non-
parametric group comparisons were performed to test for differences in the distribution 
of patient characteristics. Multiple logistic regression analysis was applied to further 
investigate the independent association between treatment success and patient 
characteristics. The final model included significant patient characteristics (e.g. p-value 
<0.05) resulting from the bivariate analysis. To minimise confounding socio-
demographics as well as addiction and infection specific characteristics were included 
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into the model, irrespective of the significance level. Goodness of fit of the final model 
was tested by applying the Hosmer-Lemeshow test. A two-sided p-value of <0.05 was 
considered statistically significant. All statistical analysis was performed using STATA 
for Windows (version 12.1; Stata Corp., College Station, Texas). 
 
RESULTS 
Population 
Between 2002 and 2010, we initiated HCV treatment in 66 opioid-dependent patients 
(80% male) with a median (IQR) age of 40 (33.7-44.2) years at the beginning of 
treatment. 50% (n=33) of patients had genotype 3, 32% (n=21) genotype 1, 14% (n=9) 
genotype 4 and 4% (n=3) genotype 2. Baseline viral load was below 800’000IU/ml in 
41% (n=27).  
The median duration of opioid maintenance treatment (OMT) before HCV treatment 
was 24.5 months (IQR 8.6-77.2). 36% (n=24) of all patients had one, 32% (n=21) had 
two or more additional substance abuse diagnoses (e.g. cocaine, benzodiazepine, 
cannabinoid or alcohol dependence). During HCV treatment, 70% (n=45) of patients 
received opioid substitution treatment (OMT) with methadone, buprenorphine or 
morphine, 21% (n=14) were treated with heroin and 9% (n=7) were not substituted at 
all. 69% of all patients declared an active or former injection drug use. 40% of all 
patients reported injecting drug use during HCV treatment. A majority of patients (77%) 
used illicit drugs, including injecting and non-injecting drugs, during HCV treatment. 21 
patients (32%) reported alcohol intake on a regular basis.  
 
In the study population, psychiatric co-morbidities were diagnosed in 83% (n=54), HIV 
co-infection in 11% (n=7). The socio-economic characteristics of the patients before 
initiation of HCV treatment are shown in table 1. 
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HCV treatment outcome 
41 out of 66 patients (62%) achieved SVR. In 5 patients without follow-up a negative 
HCV-RNA has been documented at the end of treatment. Therefore, among patients 
with available follow-up information required to assess SVR, an SVR of 67% (41 of 61) 
was reached.  
85% (28 of 33) of patients with genotype 3 achieved SVR, 33% (7 of 21) with genotype 
1, 67% (2 of 3) with genotype 2, and 44% (4 of 9) with genotype 4. In bivariate 
analysis, there was a significant difference in SVR across genotypes (p<0.001), which 
was mainly related to the SVR in genotype 3 (84%, 28 of 33) in comparison to the ‘non-
3’ genotypes with a composite SVR of 39.4% (13 of 33). 
Nine out of the 14 patients with heroin treatment had genotype 3, two had genotype 4 
and three had genotype 1. 64% (n=9) of the patients treated with heroin achieved SVR 
(8 with genotype 3, 1 with genotype 4). 
In the group of HIV co-infected patients (n=7), three had genotype 3, three genotype 1 
and one had genotype 2. Out of the seven HIV co-infected patients, 43% (n=3) 
achieved SVR. 
 
Number of consultations, duration of treatment and reasons for treatment failure 
During their treatment, 49% (n=30) of patients were seen at our clinic at least once a 
week, 40% (n=25) had a consultation at least every two weeks and only 11% (n=7) had 
less than one consultations every two weeks (missing of data in 4 cases).  
45 patients received HCV treatment as intended in the protocol. 21 patients had to 
terminate HCV treatment at an early stage, 15 of them due to medical reasons. 9 drop 
outs had a viral failure (2 with breakthrough, 7 non-responders). In 5 cases we had to 
stop the treatment at an early stage because of severe medical conditions (2 due to 
anaemia, 1 due to leucopoenia, 1 due to severe loss of weight and diarrhea and 1 due 
to Bartter-Schwarz syndrome). Nevertheless, these 5 patients achieved SVR.   
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Reasons for drop-out, treatment failure and outcome are shown in detail in figure 1.  
 
Patient factors for treatment success  
Detailed bivariate comparisons of patient characteristics according to SVR status are 
listed in table 2. In addition to HCV genotype, a longer duration of OMT, more 
consultations per week and self-reported poor physical condition were associated with 
non-SVR. Illicit drug use, including injecting and non-injecting drugs, during HCV 
treatment was not associated with SVR. 
Longer OMT duration and non-genotype 3 remained independently associated with 
non-SVR in a multiple logistic regression model controlling for the following covariates: 
age, sex, number of consultations per week, self-reported physical health, heroin 
treatment, injecting drug use and illicit drug consumption and alcohol consumption 
during HCV treatment, HIV-co-infection and number of additional substance abuse 
disorders. Corresponding adjusted odds ratios for OMT duration (per month) and non-
genotype 3 for treatment failure were 1.04 (p=0.016), and 39.4 (p=0.010). A goodness 
of fit test of the final model did not reveal a violation of the regression assumptions. 
There was a significant and inverse association between self-reported physical health 
categories (good, moderate, poor) and weekly number of consultations. Corresponding 
median (IQR) weekly consultations for good, moderate and poor self-reported physical 
health were as follows: 0.8 (0.7-1.4); 1.0 (0.6-1.3) and 1.5 (1.1-2.2) (p=0.022 and 
p=0.026 for the comparison between poor vs. moderate and poor vs. good physical 
health respectively).  
 
 
DISSCUSION  
In our study, we have demonstrated feasibility of providing HCV treatment successfully 
within an integrated primary care based setting to a multi-morbid population of people 
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who use drugs. 62% of the patients achieved SVR. The patients with HCV genotype 3, 
the most common genotype within the population of PWUD in Europe, achieved an 
SVR rate of 84%. A high percentage (over 80%) of the patients was diagnosed with a 
psychiatric co-morbidity and 10% were co-infected with HIV. Despite OMT, 70% of 
patients used illicit drugs (34% even injecting drug use) during HCV treatment. In the 
group of patients with prescribed heroin, the SVR rate of 64% was comparable to the 
overall SVR rate. So HCV treatment is also feasible in heroin maintenance treatment. 
Comparisons of patient characteristics according to SVR or non-SVR showed some 
significant factors for not reaching SVR (non-SVR). Not surprisingly, the genotype ‘non 
GT 3’ was one of the factors. A longer duration of OMT, more consultations per week 
during HCV treatment and poor self-reported physical condition were also associated 
with non-SVR. In multivariable logistic regression analysis, only ‘non-GT-3’ and a 
longer duration of OMT remained significantly associated with HCV treatment failure. 
We assume that a longer duration of OMT is an indicator of poorer psychosocial and 
physical condition and reduced stability. This instability could influence HCV treatment, 
e.g. by reducing tolerability of side effects leading to reduction of dosage of antiviral 
therapy or by reducing adherence to the treatment. Notably, the on-going illicit use of 
drugs, even injecting drug use, was not a factor for not reaching SVR.  
As we offered support according to individual needs, our patients claimed more 
supportive care und counselling than is recommended in treatment schedules for 
patients without drug use (12). Almost half of the patients required, on average, one 
consultation per week during the whole HCV treatment. Around 40% of the patients 
needed a consultation every two weeks. On the one hand, the intensive integrated care 
is probably one of the reasons for the treatment success in this hard-to-reach 
population. On the other hand, the observed correlation between self-reported physical 
health and number of consultations, both associated with treatment failure, also 
suggests a non-linear association between the demand of care and non-SVR.  
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A main strength of our study is the inclusion of patients regardless of on-going illicit 
drug use, intake of alcohol and psychiatric co-morbidities. This population represents in 
a realistic way the difficult-to-treat population of multimorbid PWUD. A further strength 
is the inclusion of patients in heroin maintenance treatment programs, as this could be 
a possible setting to reach those patients and provide them with HCV treatment. We 
are aware of several limitations of our study. The retrospective analysis and the absent 
control group are the major limitations. Another limitation is the self-reported drug use. 
However, because the use of drug had no consequences for the patients, such as 
exclusion from HCV treatment or substitution therapy, we assume high validity of the 
data (13, 14).  
 
Our results correspond with other studies demonstrating the feasibility of HCV 
treatment of PWUD with comparable SVR rates to patients without drug use in different 
settings (7-10, 15-22). As we did in our study, they describe that OMT with a 
multidisciplinary approach is a safe and successful opportunity to treat PWUD for HCV 
(18, 23-27). However, in some of these studies, patients with active drug use and/or 
alcohol intake and/or HIV infection were excluded or not described in detail. Therefore, 
our study population indicates to a greater extent the multimorbid difficult-to-treat 
population of PWUD including patients in heroin treatment programs. As far as we 
know, there is only one published study about HCV treatment in heroin treatment 
programs with a population of 21 patients (28) with SVR rates comparable to our small 
sample.  
 
A main feature of our HCV treatment setting is the provision of health care services in 
an integrated primary care based (all under one roof) setting. Primary care based 
settings for HCV treatment for either patients without drug use or PWUD have rarely 
been described (29-31). Hence we present a relatively unique possible setting for HCV 
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management in PWUD. To integrate HCV treatment in OMT with primary care facilities 
seems to be a promising approach because if patients are referred to a specialized off-
site clinic for HCV treatment, less than a third will attend (32). An advantage of 
integrating HCV treatment in primary care is its low threshold service, which facilitates 
treatment uptake. Offering easily accessible HCV treatment means reaching more 
patients of the marginalised population of PWUD. Thus the primary care setting is in all 
likelihood the most suitable setting to increase HCV treatment uptake in this hard-to-
reach population.  
There is increasing evidence that patients with chronic diseases such as heart failure 
and diabetes benefit from integrated care models (33-35). A strong primary care based 
approach can improve quality of care by coordinated and integrated care in chronically 
ill patients. If we consider HCV infection as a chronic condition, an integrated primary 
care based treatment would be the appropriate approach. A recent randomized 
controlled trial of an integrated care intervention (36) demonstrated a significantly 
higher HCV treatment eligibility compared to the standard care group, suggesting a 
treatment expansion to underserved populations. These findings support our 
hypothesis that PWUD would benefit from such an approach.  
 
We want to point out in particular the individualised and need-adapted approach we 
offered in our integrated setting. We offered as many consultations during the HCV 
treatment for supportive care as needed instead of predetermined appointments. As far 
as we know, this is the first study to take into account the individualised support. In 
previous studies the frequency of consultations was described as ‘weekly’, ‘several 
times per week’ or ‘as needed’ (18, 23, 25, 31, 37) but so far has not been integrated in 
the analyses.  
The need-adapted approach in our setting implies more effort with more supportive 
care for the patients. Consultations on a need-based frequency during HCV treatment 
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could improve the understanding of the treatment and therefore the handling of side 
effects for both the patient and the physician involved. This personalised support could 
help the patient complete the treatment. Maybe the major advantage of our clinic is the 
emphasis on the low threshold to treatment and staff-patient relationships, as patients 
are well known by the staff. According to our findings with regard to the extensive 
support we gave to the patients, only few stopped treatment early on due to personal 
reasons. There are only a few prospective studies with randomized control groups 
reviewing the effects of different support strategies on hepatitis C treatment outcomes 
in PWUD (38). 
 
Another aspect of our study we would like to point out is the potential impact of HCV 
treatment in the population of PWUD on public health. Mathematical modelling predicts 
that scaling up treatment uptake could have a positive impact on HCV prevalence and 
therefore reducing the risk of infection (39, 40). As long as treatment rates especially in 
the hard to reach population of PWUD remain low, the future highly effective and well 
tolerated antiviral agents will have limited global impact. So treatment settings that 
enhance treatment uptake might have the potential to affect public health by reducing 
HCV prevalence. Increasing the availability of treatment settings as described in our 
study could help scale up treatment uptake in PWUD.  
The question which the most efficient and cost-effective HCV treatment setting for a 
multi-morbid collective of PWUD is remains unanswered. Another question that has not 
been answered is whether our approach is as cost-effective as HCV treatment for 
PWUD is in general (41).  
We conclude that offering HCV treatment in an integrated primary care based setting 
with OMT and individualised use of different supporting strategies allows for treatment 
success rates in the multi-morbid population of PWUD which is comparable to the ones 
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in the population of patients without drug use. Furthermore, heroin maintenance 
treatment programs offer a feasible and safe setting for providing HCV treatment. 
Using integrated primary care based multidisciplinary management strategies for 
chronic care seems to be a promising way to optimise treatment uptake and the 
treatment itself in the underserved population of PWUD. To enhance treatment uptake 
rates, more integrated primary care based settings should be set up. Therefore, 
addiction treatment programs with OMT should provide on-site HCV treatment for their 
patients.  
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TABLES AND FIGURES 
Table 1: Socio-economic characteristics of the study population (n=66) before initiation of HCV 
treatment 
Characteristic 
 
n (%) 
Living with partner 23 (37.7%) 
Permanent accommodation 57 (93.4%) 
Income 
Employment (full-time or part-time) 
Disability benefits  
Social welfare 
 
15 (25.0%)  
20 (33.3%) 
25 (41.7%) 
Mental condition* 
Good 
Moderate 
poor 
 
18 (40.0%)  
24 (53.3%) 
3 (6.7%) 
Physical condition* 
Good 
Moderate 
poor 
 
21 (46.7%) 
17 (37.8%) 
7 (15.6%) 
Socioeconomic condition* 
Good 
Moderate 
Poor 
 
18 (41.9%) 
21 (48.8%) 
4 (9.3%) 
Due to missing’s 100% does not correspond to the total number of patients (n=66)  
*self-assessment 
 
Table 2. Numbers of consultations during HCV treatment 
Consultations Median (IQR)/n (%) 
Total number of consultations during treatment (N)) 26.5 (18.8-39) 
Number of consultations per week during treatment  1 (0.6-1.3) 
At least one consultation/week of treatment (%) 30 (48.4%) 
At least one consultation/two weeks of treatment (%) 25 (40.3%) 
Less than 2 consultations/two weeks of treatment (%) 7 (11.3%) 
Due to missings (n=4), 100% does not correspond to the total number of patients (n=66)) 
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Table 3: bivariate comparison between the SVR and ‘non-SVR’ group 
 SVR 
(n=41) 
Non-SVR 
(n=25) 
p-value for 
comparison 
between groups 
Male 
Female 
32 (78.0) 
9 (22.0) 
21 (84.0) 
4 (16.0) 
 
0.5 
Age at start of treatment 38.5 (32.4-43.4) 41.5 (36.8-47.1) 0.089 
Maintenance medication: 
  Methadone, buprenorphine or 
morphine 
  Heroin 
  None 
 
29 (70.7)  
9 (22.0) 
3 ( 7.3 ) 
 
17 (68)  
5 (20) 
3 (12 ) 
 
 
 
0.8 
Heroin treatment 
  yes 
  no 
 
9 (22.0)  
32 (78.0) 
 
5 (20.0) 
20 (80.0) 
 
 
0.5 
OMT duration (months) 17 (7-38) 72 (13-120) 0.018 
IDU ever  
yes 
no 
 
29 (70.7) 
12 (29.3) 
 
15 (65.2) 
8 (34.8) 
 
 
0.6 
Comorbidities IDC 10; F1 
  opiate diagnosis only 
  one additional diagnosis of   
substance abuse 
  two or more additional diagnoses of 
substance abuse 
 
14 (34.2) 
14 (34.2) 
 
13 (31.6) 
 
7 (28.0) 
10 (40.0) 
 
 8 (32.0) 
 
 
 
 
0.8 
Mental comorbidity (other than ICD 
10: F1) 
  yes 
  no 
 
31 (75.6) 
10 (24.4.9) 
 
23 (92.0) 
2 (8.) 
 
 
0.2 
HIV co-infection 
  yes 
  no 
 
3 (7.3)  
38 (92.7) 
 
4 (16.0) 
21 (84.0) 
 
 
0.4 
Living with partner 
  yes 
  no 
 
13 (35.1) 
24 (64.9) 
 
10 (41.7) 
14 (58.3) 
 
 
0.6 
Permanent accommodation 
  yes 
  no 
 
36 (97.3) 
1 (2.7) 
 
21 (87.5) 
3 (12.05) 
 
 
0.3 
Income 
  employment (full-time or part-time) 
  disability benefits  
  social welfare 
 
10 (27.0) 
10 (27.0 
17 (46.0) 
 
5 (21.7) 
10 (43.5) 
8 (34.8) 
 
 
 
0.4 
Mental condition* 
  good 
  moderate 
  poor 
 
12 (42.9) 
15 (53.5) 
1 (3.6) 
 
6 (33.3) 
9 (50.0) 
3 (16.7) 
 
 
 
0.7 
Physical condition* 
  good 
  moderate 
  poor  
 
12 (42.9) 
14 (50.0) 
2 (7.1) 
 
9 (52.9) 
3 (17.7) 
5 (29.4) 
 
 
 
0.038 
Socio-economic condition* 
  good 
  moderate 
  poor  
 
11 (40.7) 
13 (48.2) 
3 (11.1) 
 
7 (43.7) 
8 (50.0) 
1 (6.3) 
 
 
 
1.0 
Median number of weekly 
encounters (IQR) 
0.8 (0.5-1.2) 1.2 (0.8-1.5) 0.024 
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Due to missing’s 100% does not correspond to the total number of patients (n=66) *self-
assessment 
 
 FIGURE 1: SVR rates per genotyp  
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FIGURE 2: Reasons for drop-out and treatment failure 
 
 
Et.Neg = End of treatment HCV-RNA negative, Lost of follow up 
 
 
 
 
